Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma

  • Authors:
    • Henan Zhao
    • Tie Bi
    • Zhenyun Qu
    • Jiyong  Jiang
    • Shiying  Cui
    • Yan Wang
  • View Affiliations

  • Published online on: July 7, 2014     https://doi.org/10.3892/or.2014.3311
  • Pages: 1003-1012
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoresistance is a major challenge to successful chemotherapy of ovarian cancer, which represents the leading cause of mortality from gynecologic malignancies. We demonstrated that overexpression of miR-224-5p in ovarian cancer patients is associated with platinum-based chemoresistance using miRNA microarray analysis and quantitative real-time polymerase chain reaction (qRT-PCR) validation in vivo, as well as in 4 human ovarian cancer cell lines (C13/OV2008; A2780CP/A2780S) in vitro. In the present study, we aimed to clarify the role of miR-224-5p in regulating the chemoresistance of ovarian cancer. By using the sensitive miRNA transient transfection, we demonstrated expression and bioactivity of miR-224-5p in ovarian cancer cell lines. It is of note that enforced expression of miR-224-5p enhanced chemoresistance to cisplatin in ovarian cancer cells through apoptosis reversion. We predicted and identified the PRKCD gene as one of the targets of miR-224-5p in mediating the primary chemoresistance of ovarian cancer patients. We showed reciprocal expression of miR-224-5p and PRKCD by quantitative analysis in complete response and incomplete response patients in vivo, and 2 pairs of cisplatin resistance and sensitive cell lines in vitro, after either miR-224-5p overexpression or knockdown transfection. Additionally, miR-224-5p and PRKCD can serve as novel predictors and prognostic biomarkers for ovarian papillary serous carcinoma (OPSC) patient response to overall disease-specific survival. Our findings suggest that miR-224-5p may function as an oncogene and induce platinum resistance in OPSC at least in part by downregulating PRKCD, thereby providing a biomarker for predicting chemosensitivity to cisplatin in patients with ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

September-2014
Volume 32 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao H, Bi T, Qu Z, Jiang J, Cui S and Wang Y: Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. Oncol Rep 32: 1003-1012, 2014
APA
Zhao, H., Bi, T., Qu, Z., Jiang, J., Cui, S., & Wang, Y. (2014). Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. Oncology Reports, 32, 1003-1012. https://doi.org/10.3892/or.2014.3311
MLA
Zhao, H., Bi, T., Qu, Z., Jiang, J., Cui, S., Wang, Y."Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma". Oncology Reports 32.3 (2014): 1003-1012.
Chicago
Zhao, H., Bi, T., Qu, Z., Jiang, J., Cui, S., Wang, Y."Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma". Oncology Reports 32, no. 3 (2014): 1003-1012. https://doi.org/10.3892/or.2014.3311